The global encephalitis treatment market is currently valued at USD 20.14 Billion in 2023 and is anticipated to expand at a CAGR of 5.4%. Owing to the technological advances in healthcare the market is likely to propel to USD 34.08 Billion by 2033.
The increasing prevalence of encephalitis and increasing favorable initiatives to combat the disease with appropriate diagnosis and treatment options are expected to boost market growth during the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 20.14 Billion |
| Projected Forecast Value (2033) | USD 34.08 Billion |
| Global Growth Rate (2023 to 2033) | 5.4% CAGR |
Encephalitis is an infection or an inflammatory response that causes inflammation of the active tissues of the brain. The encephalitis treatment's purpose is to minimize head swelling and avoid unwanted problems.
If encephalitis is caused by a bacterial infection, intravenous antibiotics can be used to treat it. Supportive treatment, as well as intravenous antiviral medication with acyclovir, are used to treat herpes-related encephalitis. Other therapies include lowering the fever, hydrating the patient, treating seizures if they occur, and reducing any pressure in the skull.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Growing Incidences of Encephalitis to Drive the Market Growth
The major factor attributing to the growth of the market is the high mortality and morbidity rate caused due to the incidence of encephalitis virus. Furthermore, increasing government initiatives for vaccination programs is boosting the market. For instance, according to the World Health Organization as of April 28, 2022, 37 human cases of Japanese encephalitis (25 laboratory-confirmed cases and 12 probable cases) had been documented in four Australian states.
As the number of cases and fatalities rises, individuals must take preventive measures such as immunization, which increases demand for encephalitis treatment, thereby boosting market growth.
The rise in the incidences of cancer will act as a major driver that will result in the expansion of the growth rate of the market. When the body is fighting cancer, certain immune system illnesses might induce encephalitis which will increase the occurrence rate of encephalitis.
Growing Investment for Healthcare Infrastructure to Boost the Market Growth During Forecast Period.
Another significant factor influencing the growth rate of the encephalitis treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, the increase in the popularity of physical therapy across the globe will enhance the growth of the encephalitis treatment market. Furthermore, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the encephalitis treatment market.
Other factors such as an increase in the demand for effective therapies and rising spending on public health programs will positively impact the encephalitis treatment market's growth rate.
Additionally, high disposable income, a rising geriatric population, and changing lifestyles will result in the expansion of the encephalitis treatment market. Increasing research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.
For instance, in August 2021, Pfizer received United States Food and Drug Administration (USFDA) approval for Tick-Borne Encephalitis (TBE) Vaccine named TICOVAC. It can produce neutralizing antibodies against the TBE virus in the wild. TICOVAC contains albumin, a human blood product. It carries a very low risk of transmission of viral illness and variant Creutzfeldt-Jakob disease (vCJD) transmission because of efficient donor screening and product production processes.
Lack of Skilled Professionals May Hamper the Market Growth
Although the encephalitis treatment market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth.
The high cost associated with the treatment and the lack of infrastructure in low-income countries will impede the growth rate of the encephalitis treatment market. Additionally, the dearth of skilled professionals will hinder the encephalitis treatment market growth. Less awareness among patients will further challenge the market in the forecast period mentioned above.
Principal Consultant
Advancement in Healthcare to Boost the Market Growth in Region
The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 5.2% during the forecast period.
The high prevalence of the disease together with the presence of many leading market players in the region is expected to boost the growth of the North American encephalitis treatment market in the years to come.
Encephalitis affects 10-15 persons per 100,000 each year, with over 250,000 cases diagnosed in the USA in the last decade. The illness can affect anyone, but it is more common in children and teenagers. The HIV-infected population accounts for about 15% of encephalitis cases.
Incidence of encephalitis in children in the US has increased over the past 10 years which may be partially attributed to the increasing use of immunosuppressive therapies and bone marrow and solid organ transplantation associated with an increased risk of encephalitis, as well as improved sensitivity of brain parenchymal imaging using magnetic resonance imaging (MRI).
Increasing Investment in Healthcare Infrastructure Provides an Opportunity for Market Growth
Europe is expected to have the second maximum market share of the encephalitis treatment market due to the high number of people suffering from COPD and asthma in the region.
In addition, the high adoption rate of advanced diagnostic devices, easy obtainability of diagnostic test kits, increasing awareness about early diagnosis, and increased number of diagnostic centers are also expected to fuel region expansion during the forecast period. Moreover, various government initiatives to promote the diagnosis of various infectious diseases are likely to offer lucrative growth opportunities during the coming year.
Increasing Prevalence of Japanese Encephalitis in the Region to Boost the Market Growth
The Asia Pacific encephalitis treatment market is expected to rise at a CAGR of 5.1% from 2023 to 2033. Asia Pacific dominates the encephalitis treatment market owing to the high geriatric population and increasing disease burden in economies such as India, China, and South Korea.
According to the updates from European Centre for Disease Prevention and Control in March 2022, the Japanese Encephalitis virus can be found throughout Asia and Oceania, from Japan to India, Pakistan, and Australia.
The growing healthcare industry and an aging population consequently would lead to an increased patient population in these countries. India, China, and Brazil are expected to be rapidly growing markets, owing to an increase in investments by governments in order to enhance healthcare facilities.
Growing investment in the Research and Development sector, entry of new vaccine manufacturers in countries like India and China, an increasing number of travelers in the region, and medical tourism is propelling the market growth in the region.
| United Kingdom | 5.1% |
|---|---|
| India | 5.1% |
| South Korea | 5.0% |
| China | 4.8% |
| United States of America | 5.2% |
Hospital Segment Remains Dominant Among Other Types
The hospital segment held the largest market share of 50.5% in 2023 owing to the wide adoption of advanced technology in hospital settings. The availability of various treatment options in such facilities increases the number of visits for encephalitis diagnosis and treatments, which, in turn, supports segment growth.
The clinic's end-user segment is estimated to register the fastest CAGR from 2023 to 2033. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the encephalitis treatment market.
Some of the start-ups in the encephalitis treatment market include-
Some of the key players present in the global encephalitis treatment markets are Allergan, Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Melinta Therapeutics LLC, Basilea Pharmaceutica Ltd., Abbott, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR 5.4% from 2023 to 2033 |
| Expected Market Value (2023) | USD 20.14 Billion |
| Projected Forecast Value (2033) | USD 34.08 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Treatment, End-Users, Regions |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Allergan; Merck & Co., Inc.; Pfizer Inc.; GlaxoSmithKline plc; Melinta Therapeutics LLC; Basilea Pharmaceutica Ltd.; Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Teva Pharmaceutical Industries Ltd.; Sanofi |
| Customization | Available Upon Request |
This market is estimated to reach USD 34.08 billion by 2033.
Advancements in healthcare boost the market growth.
The lack of skilled professionals restrains the market growth.
Growing incidences of encephalitis drive the market growth.
The United States holds a substantial share of the market.
1. Executive Summary | Encephalitis Treatment Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Antiviral Agents 5.2. Steroid Injection 5.3. Antibiotics 5.4. Immunoglobulin Therapy 5.5. Plasmapheresis 5.6. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users 6.1. Clinic 6.2. Hospital 6.3. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Allergan 15.2. Merck & Co., Inc. 15.3. Pfizer Inc. 15.4. GlaxoSmithKline plc 15.5. Melinta Therapeutics LLC 15.6. Basilea Pharmaceutica Ltd. 15.7. Abbott 15.8. F. Hoffmann-La Roche Ltd. 15.9. Teva Pharmaceutical Industries Ltd. 15.10. Sanofi 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Encephalitis Treatment Market
